These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

948 related items for PubMed ID: 23479136

  • 1. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 2. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 3. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E, Kim D, Makarević J, Reiter M, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
    Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A.
    Oncotarget; 2015 Aug 28; 6(25):21614-27. PubMed ID: 26057634
    [Abstract] [Full Text] [Related]

  • 8. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin RA, Kim HL.
    PLoS One; 2013 Aug 28; 8(1):e54918. PubMed ID: 23349989
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H, Ichiyanagi O, Naito S, Bilim VN, Tomita Y, Kato T, Nagaoka A, Tsuchiya N.
    BMC Cancer; 2016 Jul 07; 16():393. PubMed ID: 27387559
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 07; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M, Enokida H.
    Cancer Sci; 2020 May 07; 111(5):1607-1618. PubMed ID: 32232883
    [Abstract] [Full Text] [Related]

  • 18. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.
    J Surg Res; 2013 Nov 07; 185(1):225-30. PubMed ID: 23769634
    [Abstract] [Full Text] [Related]

  • 19. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.
    Anticancer Res; 2015 Apr 07; 35(4):1951-9. PubMed ID: 25862847
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.